According to latest reports from The Economic Times, Marksans Pharma shares surged over 9% to ₹306.20 following exceptional Q1FY27 results. The company delivered its highest-ever quarterly performance with consolidated net profit jumping 174% year-on-year to ₹159 crore from ₹58 crore in the corresponding quarter of the previous year. Operating revenue increased 35.6% year-on-year to ₹841 crore, while EBITDA reached an all-time quarterly high of ₹213 crore, rising 113% year-on-year from ₹100 crore in the same quarter last year. EBITDA margin expanded significantly to 25.3% from 16.1% a year ago and 22.8% in Q4FY26, demonstrating strong operational efficiency improvements across all key metrics.
As reported by The Economic Times, the company's UK and Europe formulation business recorded its highest-ever quarterly revenue of ₹356 crore, up 74.7% year-on-year, marking the strongest quarter for the UK business. Managing Director Mark Saldanha stated that Q1FY27 has been a strong start to the year, with an all-time high quarterly EBITDA of ₹213 crore and PAT of ₹159 crore, reflecting the strength of the company's underlying business. Growth in the region was supported by new product launches, continued market share gains in the UK, and a strong order pipeline. The company completed the 100% acquisition of Netherlands-based QliniQ and Germany-based ABCnow GmbH during this quarter, with QliniQ contributing ₹44 crore to Q1FY27 revenue, marking an important first step in the company's European expansion.
According to The Economic Times, the US and North America formulation business reported revenue of ₹377 crore, up 15.1% year-on-year, accounting for around 45% of consolidated revenue growth year-on-year. Growth was supported by a healthy order book and new product launches. Australia and New Zealand businesses reported revenues of ₹88 crore in this quarter, with a growth of 53.7% YoY, supported by continued portfolio expansion and new product launches. The Rest of the World (RoW) business reported revenue of ₹20 crore, down 36.8% year-on-year, though it improved 6% sequentially, with Middle East shipments impacted by delays. Total expenses increased 20.14% year-on-year to ₹659.63 crore, with cost of materials consumed rising 14.5% to ₹220.67 crore and employee benefits expense increasing 16.17% to ₹114.29 crore.
As reported by The Economic Times, Marksans' cash balance crossed the ₹1,000-crore mark for the first time, reaching ₹1,058 crore at the end of Q1FY27, despite recent acquisitions of QliniQ and ABCnow. Managing Director Mark Saldanha said the strong balance sheet provides the company with the financial strength and flexibility to continue investing in organic growth while pursuing calibrated inorganic opportunities. The company plans to focus on scaling its businesses across geographies, accelerating new product launches, and further strengthening its European platform. Looking ahead, Saldanha emphasized that the combination of broad-based growth, expanding margins, and a strong balance sheet positions Marksans well for the next phase of sustainable growth.
